TobaccoPurpose –The aim of this paper is to examine the confusion and misperceptions regarding the actual risk involved in smokeless tobacco use as an alternative nicotine delivery option for inveterate smokers.Design/methodology/approach –The paper cites published research and current government ...
The role of smoke-free products in tobacco harm reduction The best way to avoid the harm of smoking is to not start in the first place. For someone who already smokes, quitting smoking is the single best thing they can do to reduce their risk. And if a person won’t quit, then ...
Featured Omni™ – Forward Thinking for a Smokeless World Intended for scientists, public health authorities, regulators, policy makers, and investors, the Omni™ offers a summary of the global Tobacco Harm Reduction evidence base created over the last decade. ...
Our focus is to make tobacco harm reduction a reality for millions of adult smokers who don’t quit. They should have access to better alternatives to cigarettes, like heated tobacco products, e-cigarettes, and oral smokeless products that are acceptable in taste and sensory experience, making ...
Harm reduction Communicating Tobacco Health Effects The public should be guided by the messages of the U.S. Surgeon General, the FDA and other public health authorities worldwide in making decisions concerning the use of tobacco products.
The most promising harm reduction products are high dose pharmaceutical nicotine preparations and low nitrosamine smokeless tobacco, such as Swedish snus. However, despite widespread availability, existing pharmaceutical nicotine preparations have not been taken up by smokers as an alternative to smoking. ...
One panel of experts estimated a 90% reduction in relative risk of low-nitrosamine smokeless tobacco use in comparison with smoking (Levy et al., 2004). However, these products are discursively separated from medicinal nicotine, and the majority of mainstream public health and tobacco control organ...
Smokers’ perceptions of smokeless tobacco and harm reductiondoi:10.1057/jphp.2012.9smokelesstobaccoharmreductiontobaccocontrolqualitativedomainanalysisExisting survey data indicate that most smokers are not receptive to harm reduction incentives of switching to smokeless tobacco (SLT). Little is known about ...
But, there is a third choice for smokers: tobacco harm reduction. It involves the use of alternative sources of nicotine, including modern smokeless tobacco products like snus and the electronic cigarette (E-cig), or even pharmaceutical nicotine products, as a replacement for smoking. E-cigs ...
from Western-style smokeless tobacco use are clearly below the limits of what we can detect via the extensive epidemiology. We also have a tiny bit of evidence about the use of pharmaceutical nicotine, mostly the same exposure as vaping, which further supports this. (We have limited data ...